J&J, Bristol Myers lose challenges to US drug price negotiation program

A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb (BMY.N) and Johnson & Johnson (JNJ.N) to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.